Last reviewed · How we verify
MMR（0d），HPV（1m），HPV（7m）
This is a vaccination schedule combining MMR (measles, mumps, rubella) and HPV (human papillomavirus) vaccines to provide immunization against these viral infections.
This is a vaccination schedule combining MMR (measles, mumps, rubella) and HPV (human papillomavirus) vaccines to provide immunization against these viral infections. Used for Prevention of measles, mumps, and rubella, Prevention of human papillomavirus-related cancers and infections.
At a glance
| Generic name | MMR（0d），HPV（1m），HPV（7m） |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The MMR vaccine contains live attenuated viruses that stimulate cellular and humoral immune responses against measles, mumps, and rubella. The HPV vaccine (administered at 1 month and 7 months) contains recombinant viral-like particles that elicit antibody responses against human papillomavirus types associated with cervical cancer and other malignancies. Together, this schedule provides comprehensive protection against these vaccine-preventable diseases.
Approved indications
- Prevention of measles, mumps, and rubella
- Prevention of human papillomavirus-related cancers and diseases
Common side effects
- Injection site pain, swelling, or erythema
- Fever
- Myalgia or arthralgia
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: